Psychedelics Today

PT572 – The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics Could Prevent Nuclear War, with Howard Kornfeld, MD

5 snips
Dec 10, 2024
Howard Kornfeld, a renowned pain medicine expert and addiction specialist, discusses the promise of buprenorphine as a treatment for both addiction and chronic pain, comparing it to MDMA. He shares insights on the historical context and potential of ketamine, while also warning about its risks. Kornfeld provocatively connects psychedelics to nuclear disarmament, citing their ability to change minds and promote peace. The conversation emphasizes the need for innovative research and responsible use of psychedelics in addressing global challenges.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Buprenorphine and MDMA Parallels

  • Buprenorphine's FDA approval process offers a potential roadmap for MDMA.
  • Both are controlled substances proposed for life-threatening conditions.
ADVICE

Expanded Access for MDMA

  • Explore expanded access programs for MDMA under FDA study umbrella.
  • This would allow more veterans to receive MDMA treatment.
INSIGHT

Rethinking Psychedelic Study Design

  • Double-blind studies may not be suitable for psychedelic research.
  • Explore alternative study designs like matched controls.
Get the Snipd Podcast app to discover more snips from this episode
Get the app